Insights On Drug Discovery

31. Marriage Or Roofing Contractor? Metaphors For Outsourcing 8/21/2024

    Chief Editor Louis Garguilo instigates a bit of philosophic thought in panelists Sriram Naganathan, REVOLUTION Biologics, and Kirsteen Keith, Immunocore, when it comes to strategic alliances with CDMOs.

32. Switch On The Project Manager At Your CDMO 8/21/2024

    At various points during our recent Outsourced Pharma Live, our experienced outsourcers turned their attention to “turning on” the value from PMs at your CDMO.

33. The Shifting CDMO Landscape – Don't Lose Your Balance 8/21/2024

    Our panelists describe how the landscape of today’s CDMOs continues to “shift,” what that means, and how to select and form solid partnerships within the changes.

34. The Key Questions Of Strategy For Outsourcing 8/21/2024

    Chief Editor Louis Garguilo starts off our Outsourced Pharma Live with the key questions to ask about the strategic direction of your drug development and manufacturing outsourcing.

35. Decoding A B-Cell Fingerprint: All You Need To Know 7/30/2024

    Explore how, much like a fingerprint, each B-cell possesses a unique identity, and how deciphering this code can unlock a wealth of possibilities in antibody development, immunotherapy, and beyond.

36. The Power Of The Pool: Using Bulk Cultures For Clinical Trial Manufacturing 7/29/2024

    Stable bulk cultures, made highly uniform using transposase-mediated technologies, may be the key to expediting clone selection for many biopharmaceutical applications.

37. Stable Bulk Cultures: A Fast Path To Antibody Manufacturing 7/25/2024

    The potential advantages that stable bulk cultures can offer a drug development paradigm are poised to accelerate and bolster biopharmaceutical clinical manufacturing.

38. The Value Of Tailoring Transposons For Optimized Biotherapeutic Production 7/25/2024

    By leveraging transposase-mediated technologies together with transposon design to achieve semi-targeted integration, drug developers can more efficient and consistent biotherapeutic protein production.

39. Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight 7/23/2024

    By using an optimized transient transfection platform, drug developers can accelerate their characterization and early development activities, facilitating continuity for a drug's scale-up.

40. The Scalability Of Depth Filters For CHO Cell Culture Clarification 7/19/2024

    Clarification using depth filtration is standard in monoclonal antibody (mAb) manufacturing. Here, we showcase the scalability of Stax™ mAx depth filters, demonstrating their effectiveness.